Little Green Pharma has received its first shipment of cannabis from its recently acquired facility in Denmark.
Australian medical cannabis producer Little Green Pharma (LGP), which was the first company to supply patients in the country with Australian grown medical cannabis, has received the shipment of ~50 kg of “LGP Flower THC 16 – Billy Buttons” from its Danish facility into Australia just over two months following the acquisition.
Two further shipments are expected by the end of October 2021.
Medicine for patients
The shipments are expected to help meet the growing demand in Australia for cannabis flower medicines, as dried flower sales in the country have seen an increase in demand as doctors become more comfortable with this method of administration, and with cannabis flower frequently prescribed due to its rapid onset of therapeutic benefit.
Little Green Pharma managing director, Fleta Solomon, commented: “The import of this first shipment so quickly following the acquisition is a milestone achievement by our new Denmark team. To be able to meet all the regulatory requirements to supply and import product within this timeframe is a significant achievement and consistent with our reputation as a leading global medicinal cannabis business.
“Flower medicines are becoming increasingly popular with Australian doctors in prescribing to patients for quick onset of effects, mainly for breakthrough pain or to assist with sleep, and with access to this Denmark-grown product we are able to provide a new supply chain of high-quality, medicinal cannabis flower in an under-supplied market.”
Read more: Little Green Pharma buys up huge European production operation
Solomon added: “In addition, I am very pleased to announce the appointment of Morten Snede to the role of Group CFO and Tony Roberts to the role of General Manager (EU). Both bring a huge amount of expertise in the medicinal cannabis industry to LGP, having both overseen the creation and development of significant medicinal cannabis businesses in their own right. We are very excited that they have agreed to join the LGP team and help us realise LGP’s ambition of continuously improving patient access to GMP cannabis medicines and being the leading pure-play medicinal cannabis supplier globally.”
The flower, which is grown under Good Agricultural and Collection Practices, manufactured under EU GMP, and conforms with Therapeutic Goods Order 2017, has a THC content of 16% and is available in the Australian market in 15g packs.
[activecampaign form=31]
